港股異動 | 去年業績勝預期 普拉達(1913.HK)漲5%
格隆匯1月21日丨普拉達(1913.HK)拉昇漲4.92%,報51.2港元,成交額放大至4744萬港元,總市值1304億港元。公司2021年全年總收益為33.64億歐元,按固定匯率計算較2020年增長41%及較2019年增長8%。瑞銀認為,公司業績表現勝於市場預期,這可能成為其營業利潤的突破點,故該行將2022/23財年每股盈測分別上調8%/11%。值得注意的是,這是該公司自2016財年以來首次錄得淨現金流狀況,較該行預期提前了一年。該行預計公司將在2022年延續強勢,維持買入評級,目標價68港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.